Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 95   

Articles published

ARNA 2.13 +0.01 (0.47%)
price chart
Arena Pharmaceuticals, Inc. Short Interest Update
The short interest in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has declined from 25,879,900 on October 30,2015 to 24,340,204 on November 13,2015.
Stock in Focus - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)  Vanguard Tribune
Could Arena Pharmaceuticals, Inc. Change Direction After Today's Huge ...
Arena Pharmaceuticals to Present at Piper Jaffray 27th Annual Healthcare ...
24, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Piper Jaffray 27th Annual Healthcare Conference on Wednesday, December 2, 2015 ...
Here's Why Arena Pharmaceuticals, Inc. Is Struggling Today
What: Arena Pharmaceuticals (NASDAQ:ARNA) was down as much as 12% today after its marketing partner Eisai released financial results for the first half of its fiscal year.
Needham Reiterates Hold on Arena Pharmaceuticals, Inc. (ARNA) Ahead of Earnings  Smarter Analyst
Company Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Drops by -19.23%  News Watch International
Company Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Rally 16.85%
Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) appreciated by 16.85% during the past week but lost 11.11% on a 4-week basis.
Arena Pharmaceuticals Shares Up 2.5% (ARNA)  Putnam Standard
Analysts Set Arena Pharmaceuticals PT at $4.90 (NASDAQ:ARNA)  Intercooler
Small cap stock picking: Repros Therapeutics Inc (NASDAQ:RPRX), Arena ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) closed at $2.12 with an increase of 1.92%. The $514.21M company on November 10, 2015 reported financial results for the third quarter ended September 30, 2015, and provided a corporate update.
Price Target Update on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares are expected to touch $3.75 in the short term. This short term price target has been shared by 4 analysts.
Arena Pharmaceuticals to Host Analyst & Investor Day on December 3rd  PR Newswire (press release)
Does This Provide a Reason to Buy Arena Pharmaceuticals, Inc.? The Stock Has ...
Arena: Belviq Sales Drop- Company Deploying New Strategy
Arena (NASDAQ:ARNA) investors used to look forward to seeing sales numbers for the anti-obesity drug Belviq. These days, with sales dipping lower and lower and in light of seeing dropping market share, investors are looking toward the pipeline as the ...
Arena Pharmaceuticals: A Lack Of Clarity Heading Into 2016
Investors received an interesting piece of news yesterday when the company announced that it would be laying off 35 percent of its workforce and 'shifting its strategic focus.
Arena Pharmaceuticals to lay off 35 percent of US workers  Reuters
Scorching Hot Biotech Stocks Tape: Arena Pharmaceuticals, Inc. (ARNA ...
Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
Biotech Stocks to bet on: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), CEL-SCI ...
On the trading floor, shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) gained 1.00% to close at $2.02. The $485.10M company on November 17, 2015 announced its unaudited financial results for the third quarter ended September 30, 2015.
Biotech Stocks For Your Portfolio: ImmunoCellular Therapeutics Ltd (NYSEMKT ...  Investor Wired